J.W. Cole Advisors Inc. Has $1.14 Million Stock Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

J.W. Cole Advisors Inc. lifted its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 4.5% during the 4th quarter, HoldingsChannel.com reports. The firm owned 2,760 shares of the company’s stock after buying an additional 118 shares during the period. J.W. Cole Advisors Inc.’s holdings in IDEXX Laboratories were worth $1,141,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the stock. FSA Wealth Management LLC bought a new stake in shares of IDEXX Laboratories during the 3rd quarter worth $25,000. E Fund Management Hong Kong Co. Ltd. lifted its position in shares of IDEXX Laboratories by 5,700.0% during the 3rd quarter. E Fund Management Hong Kong Co. Ltd. now owns 58 shares of the company’s stock worth $29,000 after buying an additional 57 shares during the last quarter. Retirement Wealth Solutions LLC bought a new stake in shares of IDEXX Laboratories during the 4th quarter worth $31,000. Mowery & Schoenfeld Wealth Management LLC lifted its position in shares of IDEXX Laboratories by 750.0% during the 3rd quarter. Mowery & Schoenfeld Wealth Management LLC now owns 68 shares of the company’s stock worth $34,000 after buying an additional 60 shares during the last quarter. Finally, Ashton Thomas Securities LLC bought a new stake in shares of IDEXX Laboratories during the 3rd quarter worth $37,000. 87.84% of the stock is owned by institutional investors and hedge funds.

IDEXX Laboratories Price Performance

Shares of IDXX opened at $449.06 on Wednesday. IDEXX Laboratories, Inc. has a 1 year low of $398.50 and a 1 year high of $583.39. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 1.03. The company has a market capitalization of $36.77 billion, a price-to-earnings ratio of 42.09, a price-to-earnings-growth ratio of 3.47 and a beta of 1.37. The business has a 50-day moving average of $430.82 and a 200-day moving average of $452.56.

Insider Buying and Selling

In related news, EVP George Fennell sold 9,986 shares of the firm’s stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the completion of the sale, the executive vice president now owns 8,176 shares of the company’s stock, valued at $3,781,645.28. This trade represents a 54.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Sophie V. Vandebroek sold 344 shares of the firm’s stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total value of $144,631.36. Following the sale, the director now directly owns 905 shares of the company’s stock, valued at $380,498.20. This represents a 27.54 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 13,330 shares of company stock valued at $6,161,276 over the last 90 days. Company insiders own 2.11% of the company’s stock.

Analysts Set New Price Targets

IDXX has been the subject of several recent analyst reports. Bank of America upped their price objective on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a “neutral” rating in a research report on Tuesday, February 4th. Piper Sandler increased their target price on IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a research report on Monday, February 10th. Leerink Partners assumed coverage on IDEXX Laboratories in a research report on Monday, December 2nd. They issued an “outperform” rating and a $500.00 target price for the company. Barclays increased their target price on IDEXX Laboratories from $481.00 to $520.00 and gave the company an “overweight” rating in a research report on Tuesday, February 4th. Finally, StockNews.com downgraded IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday, February 5th. Four research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $533.75.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.